A prospective trial of anti-TNF [tumour necrosis factor]-alpha chimeric monoclonal antibody (infliximab, Remicade) on insulin sensitivity, beta cell function and cardiovascular risk profile in insulin resistant human obesity
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Infliximab (Primary)
- Indications Insulin resistance; Metabolic syndrome; Obesity
- Focus Pharmacodynamics
- 04 Apr 2008 New trial record.